A similar approach has also been used to deliver PTEN mRNA, yielding promising results in PC-3 tumor models in vivo, reducing both primary and metastatic tumor growth through suppression of the PI3K–AKT signaling pathway [101]. This evidence concerns the gene AKT1 and neoplasm.